Ozempic has no BMI requirement. It is FDA-approved specifically for adults with type 2 diabetes, and the qualifying factor is your diagnosis, not your weight. If you’re searching for a BMI cutoff, you’re likely thinking of Wegovy, which uses the same active ingredient (semaglutide) but is approved for weight management with specific BMI thresholds. The distinction between these two drugs matters for what you’ll qualify for and what insurance will cover.
Ozempic Is Approved for Type 2 Diabetes, Not Weight Loss
The FDA has approved Ozempic for three purposes, all tied to type 2 diabetes. It can be prescribed alongside diet and exercise to improve blood sugar control, to reduce the risk of major cardiovascular events in people with type 2 diabetes and heart disease, and to slow kidney disease progression in people with type 2 diabetes and chronic kidney disease. None of these indications mention BMI at all.
This means a person with type 2 diabetes at any weight can potentially receive an Ozempic prescription. Your doctor will evaluate whether your blood sugar management needs improvement or whether you have cardiovascular or kidney risks that semaglutide could help address. Weight loss is a well-documented side effect of the drug, but it is not the reason the FDA approved Ozempic.
Where the BMI Numbers Come From
The BMI thresholds you’ve probably seen online (30 or 27) apply to Wegovy, not Ozempic. Wegovy contains the same compound, semaglutide, but at a higher dose and with a separate FDA approval for chronic weight management. Under that approval, you qualify if your BMI is 30 or greater, or if your BMI is 27 or greater and you also have at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes.
For adolescents aged 12 and older, the FDA expanded the Wegovy label in late 2022 to include those with a BMI at or above the 95th percentile for their age and sex.
Off-Label Ozempic for Weight Loss
In practice, many doctors prescribe Ozempic off-label for weight loss in patients who don’t have type 2 diabetes. Off-label prescribing is legal and common across medicine, but it means the doctor is making a judgment call rather than following a specific FDA indication. There is no standardized BMI cutoff that governs these decisions. Each provider evaluates your health profile individually.
That said, responsible prescribing generally follows the same logic as the Wegovy label: a BMI of 30 or higher, or 27 or higher with a related health condition. Some online pharmacies have drawn criticism for prescribing semaglutide to people with BMIs as low as 20, well below any clinical guideline. Most experts consider a BMI below 27 a signal that the drug should be discontinued or not started in the first place.
What Insurance Will Actually Cover
Even if your doctor writes a prescription, your insurance plan has its own rules. For Ozempic prescribed for type 2 diabetes, most insurers will cover it as a diabetes medication, sometimes after prior authorization. Your BMI is not typically the gating factor here; your diabetes diagnosis is.
If you’re trying to get semaglutide covered for weight loss specifically, the picture changes. A review of major U.S. commercial health plans found that most impose BMI requirements matching the Wegovy label: BMI above 30, or above 27 with at least one weight-related condition like hypertension, diabetes, or abnormal cholesterol levels. Many insurers also require documentation that you’ve tried diet and exercise programs or lower-cost medications before they’ll approve semaglutide. Some plans don’t cover weight-loss medications at all.
Key BMI Thresholds at a Glance
- Ozempic for type 2 diabetes: No BMI requirement. You need a type 2 diabetes diagnosis.
- Wegovy for weight management: BMI of 30 or higher, or BMI of 27 or higher with a qualifying health condition.
- Off-label Ozempic for weight loss: No official threshold, but most providers use the same 30/27 benchmarks as Wegovy.
- Insurance coverage for weight loss: Typically mirrors the Wegovy label requirements and may add extra steps like documented prior attempts at lifestyle changes.
Why the Same Drug Has Different Rules
Ozempic and Wegovy both deliver semaglutide, a compound that mimics a gut hormone involved in blood sugar regulation and appetite. The difference is regulatory, not chemical. Ozempic was studied and approved as a diabetes treatment, so its label reflects diabetes criteria. Wegovy was studied and approved as a weight management treatment at a higher maximum dose, so its label reflects BMI criteria. Pharmaceutical companies file separate applications for different uses, and each approval comes with its own set of prescribing rules.
This regulatory split is the source of most confusion. If your goal is weight loss and you don’t have type 2 diabetes, the relevant BMI numbers are 30 and 27, but they technically point you toward Wegovy rather than Ozempic. Whether your doctor prescribes one versus the other often comes down to insurance coverage, drug availability, and cost.